Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor
Benjamin Ducarouge,Anna-Rita Redavid,Camille Victoor,Ruxanda Chira,Aurélien Fonseca,Maëva Hervieu,Roméo Bergé,Justine Lengrand,Pauline Vieugué,David Neves,Isabelle Goddard,Mathieu Richaud,Pierre-Alexandre Laval,Nicolas Rama,David Goldschneider,Andrea Paradisi,Nicolas Gourdin,Sylvie Chabaud,Isabelle Treilleux,Nicolas Gadot,Isabelle Ray-Coquard,Stéphane Depil,Didier Decaudin,Fariba Némati,Elisabetta Marangoni,Eliane Mery-Lamarche,Catherine Génestie,Séverine Tabone-Eglinger,Mojgan Devouassoux-Shisheboran,Kathryn J. Moore,Benjamin Gibert,Patrick Mehlen,Agnes Bernet
DOI: https://doi.org/10.1038/s41418-023-01209-x
IF: 12.067
2023-08-27
Cell Death and Differentiation
Abstract:Drug resistance and cancer relapse represent significant therapeutic challenges after chemotherapy or immunotherapy, and a major limiting factor for long-term cancer survival. Netrin-1 was initially identified as a neuronal navigation cue but has more recently emerged as an interesting target for cancer therapy, which is currently clinically investigated. We show here that netrin-1 is an independent prognostic marker for clinical progression of breast and ovary cancers. Cancer stem cells (CSCs)/Tumor initiating cells (TICs) are hypothesized to be involved in clinical progression, tumor relapse and resistance. We found a significant correlation between netrin-1 expression and cancer stem cell (CSC) markers levels. We also show in different mice models of resistance to chemotherapies that netrin-1 interference using a therapeutic netrin-1 blocking antibody alleviates resistance to chemotherapy and triggers an efficient delay in tumor relapse and this effect is associated with CSCs loss. We also demonstrate that netrin-1 interference limits tumor resistance to immune checkpoint inhibitor and provide evidence linking this enhanced anti-tumor efficacy to a decreased recruitment of a subtype of myeloid-derived suppressor cells (MDSCs) called polymorphonuclear (PMN)-MDSCs. We have functionally demonstrated that these immune cells promote CSCs features and, consequently, resistance to anti-cancer treatments. Together, these data support the view of both a direct and indirect contribution of netrin-1 to cancer stemness and we propose that this may lead to therapeutic opportunities by combining conventional chemotherapies and immunotherapies with netrin-1 interfering drugs.
cell biology,biochemistry & molecular biology